SYRE vs TARS Stock Comparison
TARS currently leads SYRE in this stock comparison, with AIQ scores of 65 vs 64. The clearest difference is value, while SYRE has the stronger quality profile.
What is the main difference between SYRE and TARS?
TARS leads the current stock comparison as Tarsus Pharmaceuticals, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Spyre Therapeutics, Inc. vs Tarsus Pharmaceuticals, Inc.
TARS leads
TARS leads by 1 AIQ points, primarily on Value and Risk Resilience, but the lead has narrowed from 13 points over 30 sessions.
Fragile: 4 of 6 evidence groups support TARS, its lead is narrowing, and its current signal state is conflicted.
Spyre Therapeutics, Inc.
Tarsus Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors TARS over SYRE, 65 versus 64 as of Nov 15, 2026. TARS's advantage is driven primarily by stronger value and risk resilience, while SYRE holds the stronger quality profile. TARS also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor TARS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. TARS lead: Weakening — the AIQ differential moved from 13 to 1 points over 30 sessions.
Compare Spyre Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare SYRE and TARS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value44 vs 75TARS +31
- Quality61 vs 50SYRE +11
- Risk Resilience53 vs 59TARS +6
- Momentum81 vs 76SYRE +5
4 of 6 evidence groups favor TARS. TARS’s edge is concentrated in value and risk resilience; SYRE keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +2
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.75x)
Largest factor move: Value +2
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
TARS's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — SYRE and TARS both carry a full feed there.
The central trade-off
TARS (Tarsus Pharmaceuticals, Inc.): the stronger current systematic profile, led by value and risk resilience.
SYRE (Spyre Therapeutics, Inc.): the counter-case, on quality, momentum, technicals — but at materially higher volatility, 59.5% against 44.7%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
TARSTARS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
TARSTARS on combined revenue and EPS growth.
Value
TARSTARS on the peer-relative Value factor, by 31 points.
Momentum
SYRESYRE on the Momentum factor, by 5 points.
Lower downside
TARSTARS on Risk Resilience, by 6 points.
Analyst upside
TARSTARS on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | SYRE | TARS | Note |
|---|---|---|---|
| Implied upside to target | +18.1% | +36.1% | TARS has more room |
| Target dispersion | +11.4% | +10.1% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 18 | 10 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor TARS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 64 vs 65 |
| Fundamentals | TARS | EPS growth -161.1% vs -32.5%; TTM ROE -9.1% vs -6.4%; gross margin 50% vs 93.2%; operating margin -276.5% vs -102% |
| Valuation | TARS | Value 44 vs 75 |
| Technicals | SYRE | Price vs 50-day 13.7% vs 7.3%; vs 200-day 35.7% vs 18.1% |
| Risk Resilience | TARS | Risk Resilience 53 vs 59 |
| Analyst expectations | TARS | Target upside 18.1% vs 36.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of SYRE and TARS and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on TARS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13TARS lead: Weakening — the AIQ differential moved from 13 to 1 points over 30 sessions.
- Today
- TARS +1
- 64 vs 65
- 7 sessions ago
- TARS +4
- 62 vs 66
- 30 sessions ago
- TARS +13
- 57 vs 70
- 90 sessions ago
- SYRE +3
- 69 vs 66
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 1 bearish / 2 neutral, conflicted
Only SYRE
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.75x)
- TRIX Bullish Signal — bullish, momentum, short horizon
5 bullish / 1 bearish / 1 neutral, conflicted
Only TARS
- BB Upper Band Breach — bearish, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
Both carry 4 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish, Uptrend Structure Active.
TARS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +1.06%, AIQ +2 points).
Price and the AIQ Score both moved up over the latest session (price +4.41%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1SYRE closes the Value gap — currently 31 points behind, the largest single contributor to TARS's edge.
- 2SYRE's Low Volume Rally Warning resolves — a bearish volume rule currently active against it.
- 3TARS's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 1-point move would eliminate TARS's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
TARS leads on balance| Metric | SYRE | TARS |
|---|---|---|
| Revenue growth (YoY) | 0% | 11.9% |
| EPS growth (YoY) | -161.1% | -32.5% |
| Gross margin | 50% | 93.2% |
| Operating margin | -276.5% | -102% |
| Return on equity (TTM) | -9.1% | -6.4% |
| Debt to equity | 0 | 0.85 |
Performance
SYRE leads 4 of 6 windows| Metric | SYRE | TARS |
|---|---|---|
| 1 week (5 sessions) | 0.1% | 17% |
| 1 month (20 sessions) | 30.2% | 17.9% |
| 3 months (63 sessions) | -0.6% | 13.7% |
| 6 months (126 sessions) | 38.8% | 28.5% |
| Year to date | 217.5% | -2% |
| 1 year (252 sessions) | 343.9% | 7.3% |
Technicals
SYRE has the stronger structure| Metric | SYRE | TARS |
|---|---|---|
| RSI (14) | 59.4 | 64.8 |
| ADX (14) | 17.9 | 16.7 |
| Price vs 50-day | 13.7% | 7.3% |
| Price vs 200-day | 35.7% | 18.1% |
| Volatility (1M, annualized) | 59.5% | 44.7% |
Risk
TARS is the more resilient| Metric | SYRE | TARS |
|---|---|---|
| Beta | 1.69 | 0.56 |
| Sharpe ratio | 2.57 | 0.36 |
| Sortino ratio | 4.62 | 0.55 |
| Max drawdown | -27.8% | -32% |
| Current drawdown | -4.6% | -11.6% |
| Annualized volatility | 66.7% | 45% |
| Value at risk (95%) | -4.9% | -4.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, SYRE or TARS?
On the Algovestiq AIQ Score, TARS is the stronger of the two as of Nov 15, 2026, scoring 65 against SYRE's 64. The edge comes from value and risk resilience. SYRE is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is SYRE or TARS the better buy right now?
TARS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor TARS over SYRE?
The composite weights Quality, Value, Momentum and Risk Resilience. TARS leads Value by 31 points; SYRE leads Quality by 11 points; TARS leads Risk Resilience by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, SYRE or TARS?
Analyst price targets imply +18.1% upside for SYRE and +36.1% for TARS, so the Street currently favors TARS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, SYRE or TARS?
TARS is the better-valued of the two on the peer-relative Value factor. TARS on the peer-relative Value factor, by 31 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, SYRE or TARS?
TARS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, SYRE or TARS?
SYRE on the Momentum factor, by 5 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, SYRE or TARS?
TARS is the more resilient of the two, so the other name carries the higher downside risk. TARS on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is SYRE more profitable than TARS?
TARS leads on the comparable margin measures — gross margin 50% vs 93.2%; operating margin -276.5% vs -102%; ttm roe -9.1% vs -6.4%.
Is TARS's lead over SYRE getting stronger or weaker?
TARS lead: Weakening — the AIQ differential moved from 13 to 1 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the SYRE vs TARS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: SYRE closes the Value gap — currently 31 points behind, the largest single contributor to TARS's edge; SYRE's Low Volume Rally Warning resolves — a bearish volume rule currently active against it; TARS's conflicting signal state resolves bearish — it currently carries 5 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 12 points over 30 sessions, and a further 1-point move would eliminate TARS's advantage entirely.
What do the current signals say about SYRE and TARS?
SYRE: 4 bullish / 1 bearish / 2 neutral, conflicted. TARS: 5 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on SYRE is Golden Cross Active (bullish, long horizon). On TARS it is Golden Cross Active (bullish, long horizon).
Compare SYRE and TARS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.